Department of Psychiatry, University of California San Diego, San Diego, California, USA.
Int J Eat Disord. 2011 Apr;44(3):269-75. doi: 10.1002/eat.20807.
There has been much interest in the use of atypical antipsychotics in anorexia nervosa (AN). However, newer, more weight-neutral medications have not been studied in AN, and there are no reports of the use of antipsychotics in bulimia nervosa (BN).
We report on the treatment of eight patients (five with AN and three with BN) with aripiprazole for time periods of four months to more than three years.
All individuals had reduced distress around eating, fewer obsessional thoughts about food, weight and body image, significant lessening of eating-disordered behaviors, and gradual weight restoration where appropriate. Depression, generalized anxiety, and cognitive flexibility improved as well.
In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN.
在神经性厌食症(AN)中使用非典型抗精神病药物引起了广泛关注。然而,尚未研究新型、更能减轻体重的药物在 AN 中的应用,也没有关于抗精神病药物在神经性贪食症(BN)中应用的报道。
我们报告了使用阿立哌唑治疗 8 例患者(5 例 AN 和 3 例 BN)的情况,治疗时间为 4 个月至 3 年以上。
所有患者在进食方面的困扰减少,对食物、体重和身体形象的强迫性思维减少,饮食失调行为明显减少,体重逐渐恢复(在适当的情况下)。抑郁、广泛性焦虑和认知灵活性也有所改善。
总之,这些发现支持在 AN 和 BN 中进行阿立哌唑对照试验的必要性。